SCHEMBL6796683

SCHEMBL6796683

CC(=O)Nc1nc(COc2ccc(N)cc2)cs1

nearest known ligand 0.77

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.77
RAB9A P51151 5/20 0.77
SMN1; SMN2 Q16637 5/20 0.77
LMNA P02545 4/20 0.70
HTT P42858 4/20 0.70
ALDH1A1 P00352 2/20 0.70
CASP3 P42574 1/20 0.70
SENP8 Q96LD8 1/20 0.70
SENP7 Q9BQF6 1/20 0.70
SENP6 Q9GZR1 1/20 0.70
AOC3 Q16853 8/20 0.55
KMT2A Q03164 3/20 0.55
MEN1 O00255 2/20 0.53
MAPK1 P28482 2/20 0.53
KDM4E B2RXH2 2/20 0.53
MAPT P10636 1/20 0.53
MAOB P27338 3/20 0.49
GAA P10253 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL972254 0.88 AOC3 (0.74) NPC1RAB9ASMN1; SMN2LMNAHTT
SCHEMBL7079364 0.88 AOC3 (0.59) NPC1RAB9ASMN1; SMN2LMNAHTT
SCHEMBL3405939 0.87 RAB9A (0.77) NPC1RAB9ASMN1; SMN2LMNAHTT
SCHEMBL4871628 0.87 RAB9A (1.00) NPC1RAB9ASMN1; SMN2LMNAHTT
SCHEMBL16242472 0.85 NPC1 (0.73) NPC1RAB9ASMN1; SMN2LMNAHTT
SCHEMBL16556647 0.84 NPC1 (0.72) NPC1RAB9ASMN1; SMN2LMNAHTT
SCHEMBL971401 0.84 NPC1 (0.72) NPC1RAB9ASMN1; SMN2LMNAHTT
SCHEMBL973243 0.84 NPC1 (0.76) NPC1RAB9ASMN1; SMN2LMNAHTT
SCHEMBL972558 0.83 NPC1 (0.70) NPC1RAB9ASMN1; SMN2LMNAHTT
SCHEMBL6799338 0.83 RAB9A (0.70) NPC1RAB9ASMN1; SMN2LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 NPC1 64/4885RAB9A 3707/4885SMN1; SMN2 2504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.